{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:26Z","timestamp":1740185006848,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>AURIGA ist die gr\u00f6\u00dfte prospektive Real-World-Studie zur Behandlung eines Makula\u00f6dems (M\u00d6) nach retinalem Venenverschluss (RVV) oder eines diabetischen Makula\u00f6dems mit intravitrealem Aflibercept 2\u202fmg (IVT-AFL). Hier werden die 24-Monats-Daten der deutschen behandlungsnaiven RVV-Kohorte mit M\u00d6 pr\u00e4sentiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Behandlungsnaive RVV-Patienten mit M\u00d6 wurden mit IVT-AFL 2\u202fmg in der klinischen Routine therapiert. Prim\u00e4rer Endpunkt war die mittlere \u00c4nderung des Visus (ETDRS-Buchstaben) zu Monat\u00a012 gegen\u00fcber dem Ausgangswert. Die Analyse erfolgte deskriptiv.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es wurden 130 Patienten mit RVV (<jats:italic>n<\/jats:italic>\u202f=\u200961 [46,9\u202f%] mit Zentralvenenverschluss, <jats:italic>n<\/jats:italic>\u202f=\u200969 [53,1\u202f%] mit Venenastverschluss) untersucht. Im Mittel (\u00b1\u00a0SD) verblieben die RVV-Patienten f\u00fcr 18,4\u202f\u00b1\u20097,4\u00a0Monate in der Studie. Der mittlere Visusgewinn [95\u202f% Konfidenzintervall] betrug in der Gesamtkohorte +10,9 [7,5; 14,2] Buchstaben zu Monat\u00a012 und +9,7 [6,1; 13,3] zu Monat 24 (Baseline 56,5\u202f\u00b1\u200918,9 Buchstaben). Nach 24\u00a0Monaten hatten 67\u202f% der RVV-Patienten \u22655\u00a0Buchstaben, 40\u202f% \u2265\u202f15\u00a0Buchstaben gewonnen. Von Baseline betrug die mittlere Injektionszahl 4,4\u202f\u00b1\u20091,3 bis Monat\u00a06, 6,2\u202f\u00b1\u20092,7 bis Monat\u00a012 und 8,2\u202f\u00b1\u20094,5 bis Monat\u00a024. Die durchschnittliche Reduktion der zentralen Netzhautdicke (Ausgangswert 507\u202f\u00b1\u2009177\u202f\u00b5m) betrug in der Gesamtkohorte \u2212206 (\u2212252; \u2212160) \u00b5m nach 12\u00a0Monaten und \u2212219 (\u2212263; \u2212175) \u00b5m nach 24\u00a0Monaten. Das Sicherheitsprofil entsprach dem fr\u00fcherer Studien.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>In der deutschen AURIGA-Kohorte behandlungsnaiver Patienten mit M\u00d6 infolge RVV unter IVT-AFL-2\u202fmg-Behandlung zeigten sich im klinischen Alltag ein rascher und klinisch relevanter Visusgewinn sowie eine Reduktion der zentralen Netzhautdicke. Diese wurden trotz niedriger Injektionsfrequenz ab Monat\u00a06 \u00fcber 24\u00a0Monate weitestgehend erhalten.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-024-02051-3","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T11:01:50Z","timestamp":1720436510000},"page":"650-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aflibercept im klinischen Alltag: die AURIGA-Studie","Aflibercept in a real-world setting: the AURIGA study"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5355-5729","authenticated-orcid":false,"given":"Joachim","family":"Wachtlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Kaymak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Allmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Machewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Sch\u00fcrks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"2051_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/bjo.2007.135913","volume":"94","author":"RM Awdeh","year":"2010","unstructured":"Awdeh\u00a0RM, Elsing\u00a0SH, Deramo\u00a0VA et\u00a0al (2010) Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol 94:319\u2013323","journal-title":"Br J Ophthalmol"},{"key":"2051_CR2","unstructured":"BVA, DOG, Retinologische Gesellschaft (2018) Intravitreale Therapie des visusmindernden Makula\u00f6dems bei retinalem Venenverschluss. Therapeutische Strategien. Stand: 24. Apr. 2018"},{"key":"2051_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12955-016-0536-1","volume":"14","author":"T Bertelmann","year":"2016","unstructured":"Bertelmann\u00a0T et\u00a0al (2016) Health Qual Life Outcomes 14:132. https:\/\/doi.org\/10.1186\/s12955-016-0536-1","journal-title":"Health Qual Life Outcomes"},{"key":"2051_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/08820538.2021.1896750","volume":"36","author":"A Chatzirallis","year":"2021","unstructured":"Chatzirallis\u00a0A, Varaklioti\u00a0A, Sergentanis\u00a0T et\u00a0al (2021) Quality of Life among Patients with Retinal Vein Occlusion: A\u00a0Case-Control Study. Semin Ophthalmol 36:658\u2013664","journal-title":"Semin Ophthalmol"},{"key":"2051_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark\u00a0WL, Boyer\u00a0DS, Heier\u00a0JS et\u00a0al (2016) Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology 123:330\u2013336","journal-title":"Ophthalmology"},{"key":"2051_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00830-w","author":"A Giocanti-Aur\u00e9gan","year":"2023","unstructured":"Giocanti-Aur\u00e9gan\u00a0A, Donati\u00a0S, Hoerauf\u00a0H et\u00a0al (2023) Real-world management of macular edema secondary tor retinal vein occlusion with intravitreal aflibercept: 24\u00a0months results deom the AURIGA observational study. Ophthalmol Ther. https:\/\/doi.org\/10.1007\/s40123-023-00830-w","journal-title":"Ophthalmol Ther"},{"key":"2051_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori\u00a0NZ, Feuer\u00a0W, Rosenfeld\u00a0PJ (2010) Novel method for analyzing Snellen visual acuity measurements. Retina 30:1046\u20131050","journal-title":"Retina"},{"key":"2051_CR8","doi-asserted-by":"publisher","unstructured":"Ha M, Han K, Jung Y, et\u00a0al (2021) Is retinal vein occlusion associated with depression symptoms?: A\u00a0nationwide cohort study. Medicine (Baltimore). 100:e26937. https:\/\/doi.org\/10.1097\/MD.0000000000026937","DOI":"10.1097\/MD.0000000000026937"},{"key":"2051_CR9","doi-asserted-by":"publisher","first-page":"e001010","DOI":"10.1136\/bmjophth-2022-001010","volume":"7","author":"A Hunter","year":"2022","unstructured":"Hunter\u00a0A, Williams\u00a0M (2022) Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a\u00a0systematic review. Bmj Open Ophthalmol 7:e1010","journal-title":"Bmj Open Ophthalmol"},{"key":"2051_CR10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","volume":"137","author":"P Hykin","year":"2019","unstructured":"Hykin\u00a0P, Prevost\u00a0T, Vasconcelos\u00a0JC et\u00a0al (2019) Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A\u00a0Randomized Clinical Trial. JAMA Ophthalmol 137:1256\u20131264","journal-title":"JAMA Ophthalmol"},{"key":"2051_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ajo.2021.01.027","volume":"227","author":"JF Korobelnik","year":"2021","unstructured":"Korobelnik\u00a0JF, Larsen\u00a0M, Eter\u00a0N et\u00a0al (2021) Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study. Am J Ophthalmol 227:106\u2013115","journal-title":"Am J Ophthalmol"},{"key":"2051_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/eye.2011.92","volume":"25","author":"M Laouri","year":"2011","unstructured":"Laouri\u00a0M, Chen\u00a0E, Looman\u00a0M et\u00a0al (2011) The burden of disease of retinal vein occlusion: review of the literature. Eye 25:981\u2013988","journal-title":"Eye"},{"key":"2051_CR13","doi-asserted-by":"publisher","first-page":"20475","DOI":"10.1038\/s41598-021-00094-z","volume":"11","author":"F Okamoto","year":"2021","unstructured":"Okamoto\u00a0F, Tomioka\u00a0M, Murakami\u00a0T et\u00a0al (2021) Relationship between stereopsis and vision-related quality of life following intravitreal ranibizumab injections for central retinal vein occlusion. Sci Rep 11:20475","journal-title":"Sci Rep"},{"key":"2051_CR14","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2147\/OPTH.S140665","volume":"11","author":"A Pielen","year":"2017","unstructured":"Pielen\u00a0A, Clark\u00a0WL, Boyer\u00a0DS et\u00a0al (2017) Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol 11:1533\u20131540","journal-title":"Clin Ophthalmol"},{"key":"2051_CR15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/jth.12982","volume":"13","author":"KA Ponto","year":"2015","unstructured":"Ponto\u00a0KA, Elbaz\u00a0H, Peto\u00a0T et\u00a0al (2015) Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J\u00a0Thromb Haemost 13:1254\u20131263","journal-title":"J Thromb Haemost"},{"key":"2051_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth\u00a0U, Garcias-Arumi\u00a0J, Gerendas\u00a0BS et\u00a0al (2019) Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica 242:123\u2013162","journal-title":"Ophthalmologica"},{"key":"2051_CR17","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","volume":"396","author":"IU Scott","year":"2020","unstructured":"Scott\u00a0IU, Campochiaro\u00a0PA, Newman\u00a0NJ, Biousse\u00a0V (2020) Retinal vascular occlusions. Lancet 396:1927\u20131940","journal-title":"Lancet"},{"key":"2051_CR18","doi-asserted-by":"crossref","unstructured":"Song P, Xu Y, Zha M, et\u00a0al (2019) Global epidemiology of retinal vein occlusion: a\u00a0systematic review and meta-analysis of prevalence, incidence, and risk factors J Global Health 9:010427.","DOI":"10.7189\/jogh.09.010427"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02051-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02051-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02051-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T15:05:37Z","timestamp":1722611137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02051-3"}},"subtitle":["24-Monats-Ergebnisse der deutschen Kohorte behandlungsnaiver Patienten mit Makula\u00f6dem bei retinalem Venenverschluss unter Therapie mit intravitrealem Aflibercept","24-month results of the German cohort of treatment-na\u00efve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept"],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2051"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02051-3","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Wachtlin macht folgende Angaben: Consulting fees: Alcon, Bayer, Roche, Novartis, Appelis. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Alcon, Roche, Novartis, Appelis, Bayer. Payment for expert testimony: Bayer, Appelis, Roche. Participation on a Data Safety Monitoring Board or Advisory Board: Bayer. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Deutsche Retinologische Gesellschaft, BBAG, BVA, KV Berlin, \u00c4K Berlin, DOG, Makulakommision. H.\u00a0Kaymak macht folgende Angaben: All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.): Bayer Vital GmbH. medical writing, compensation for conducting the study. Grants or contracts from any entity: Novartis Pharma GmbH, Research funding made to Internationale Innovative Ophtalmochirurgie. Consulting fees: Hoya Holdings, Oculus Optikger\u00e4te, Apellis, Consulting fees made to Internationale Innovative Ophthalmochirurgie. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Hoya Holdings, Roche Pharma AG, Bayer Vital GmbH, Rodenstock, Johnson & Johnson, Topcon, Lumithera, VSY Biotechnology, Honoraria for lectures made to Internationale Innovative Ophthalmochirurgie. Support for attending meetings and\/or travel: Hoya Holdings, Johnson & Johnson, Bayer Vital, VSY Biotechnology, Roche Pharma AG, Financial support for attending and travel to congresses made to Internationale Innovative Ophthalmochirurgie. Participation on a Data Safety Monitoring Board or Advisory Board: Roche Pharma AG, Ora Clinical, Hoya Holdings, Honorarium for participation in Advisory Boards made to Internationale Innovative Ophthalmochirurgie. Receipt of equipment, materials, drugs, medical writing, gifts or other services: Topcon, Receipt of equipment for scientific purposes. H.\u00a0Hoerauf macht folgende Angaben: Grants or contracts from any entity: Bayer, Novartis, Roche, Abbvie. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bayer, Novartis, Roche, Abbvie, Biogen, Thea Pharma, Alcon. Participation on a Data Safety Monitoring Board or Advisory Board: Bayer, Alcon, Roche, Stadapharm, Abbvie. Stock or stock options: Bayer, Roche, Novartis. H.\u00a0Allmeier is an employee of Bayer CC AG. He was the overall responsible for the conduct of the Auriga study. T.\u00a0Machewitz is a full-time employee of Bayer Vital GmbH and he declares stock or stock options from Bayer. P.\u00a0Scholz is a full-time employee of Bayer Vital GmbH. M.\u00a0Sch\u00fcrks is a full-time employee of Bayer Vital GmbH and he declares stock or stock options from Bayer AG. N.\u00a0Feltgen macht folgende Angaben: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Speaker. Support for attending meetings and\/or travel: Meetings and travel support (speaker). Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Deutsche Retinologische Gesellschaft, Deutsche Ophtalmologische Gesellschaft, Makulakommission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die Daten dieses Beitrags basieren auf einer nicht-interventionellen Beobachtungsstudie an Menschen bei der klinische Daten aus der Behandlungsroutine dokumentiert wurden. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}